Early phase drug trial claims a breakthrough in Huntington disease. IONIS-HTT is an antisense "gene-silencing" compound,
Early phase drug trial claims a breakthrough in Huntington disease. IONIS-HTT is an antisense "gene-silencing" compound, injected in to CSF and designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington's Disease....
Source: reuters.com
First drug to reverse Huntington's disease begins human trials : The new drug, called IONIS-HTTRx, silences the gene known
First drug to reverse Huntington's disease begins human trials : The new drug, called IONIS-HTTRx, silences the gene known to be responsible for the production of a protein which causes Huntington’s
Source: telegraph.co.uk
RSS feed